Drug development

Blood cells
#Drug development #Healthcare

Novartis update on sickle cell treatment in England and Wales 

Novartis has announced that eligible patients in England and Wales will soon have routine access to Adakveo (crizanlizumab) under a Managed Access Agreement (MAA), which the company says not only helps with sickle cell disease (SCD), but also demonstrates a commitment to supporting health equity for a community that has been historically underserved,… Read More

#News

#Drug development #Drug discovery #Immunology / Virology & Vaccines #mRNA

AstraZeneca collaboration to develop RNA therapeutics  

AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisastion of the self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.  The strategic, long-term research collaboration aims to optimise and validate VaxEquity’s saRNA platform and apply it to advance novel therapeutic programmes. AstraZeneca will support VaxEquity with research and development funding and should… Read More

#News

#Collaboration #Drug development #Drug discovery #Life sciences

Brooks introduces Azenta Life Sciences to advance sample solutions 

Brooks Life Sciences Services and Products businesses will be rebranded under the creation of a new identity – Azenta Life Sciences. Azenta will bring together Brookes’ existing portfolio of life sciences products and services to deliver integrated enterprise-wide sample exploration and management solutions.  “We are excited to announce the creation of Azenta as… Read More

#News

#Biopharmaceuticals #Clinical research #Drug development #Therapeutics

Antibody-mediated therapies: meeting the challenges in R&D

By Amanda Turner, Senior Product Manager for Custom Antibody Products at Bio-Rad and Laura Moriarty, Senior Marketing Manager at Bio-Rad The global market for therapeutic antibodies represents a huge and ever-expanding opportunity for pharmaceutical developers, with the market for monoclonal antibody therapies alone being estimated to reach $300 billion by… Read More

#Editor's Choice #Exclusive Content #News

#Cell and gene therapy #Drug development

From Novartis to MiroBio: CEO to lead company growth  

MiroBio has appointed Carolin Barth as CEO to lead the company through the next major stage of its growth as its lead programme, MB272, transitions into clinical development. Dr Barth’s appointment follows other recent senior appointments including Julian Hirst, formerly of Immunocore, as CFO and Lynne Murray, formerly of… Read More

#News

#AI #AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Pharma #Technology

Exclusive interview: BenevolentAI on the future of AI

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks with Dr Orloff about his… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Drug development #Drug discovery #Microbiome #Podcast #Precision medicine

Podcast: Opportunities to improve drug discovery systems

This is the latest episode of the free DDW podcast: “Opportunities to improve drug discovery systems”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine.   The first article is titled “Precision control of protein release… Read More

#News #Trending News

#Biopharmaceutical #Drug development #Events #Webinar

Webinar: Addressing analytical challenges in biosimilar development 

The route to market for biosimilars places strong emphasis on characterisation tools for establishing comparability between biosimilar and innovator products.   Addressing analytical challenges in fast-forwarding biosimilar development processes requires Implementing sophisticated analytical instruments with advanced technologies. The ICH Q6B, cited by both EMA and FDA, highlights electrophoretic data as… Read More

#News

#Collaboration #Drug development #Drug discovery #Gene mutation #Research #Schizophrenia

This week in drug discovery (13-17 September) 

News round-up by DDW’s Megan Thomas for 13-17 September  The news in the drug discovery industry this week has demonstrated the potential that remains untapped for a number of industries at large as well as taking early steps towards future cures and treatments. DDW’s Megan Thomas has… Read More

#News #Trending News

#CRISPR #Drug development #Drug discovery #Gene editing #R&D

Benchling launch cloud solution at virtual event  

Benchling, the biotechnology cloud R&D platform used by organisations including Regeneron, Gilead and Pfizer, hosted a virtual event on September 14 at 8 am PT / 11 am ET called Drive Innovation from Discovery to Development, where the company announced its entry into the Early Development market, launching new solutions that… Read More

#News

#Drug development #Novel therapeutics

Breakthrough Therapy Designation granted in China for lymphoma drug 

Hutchmed has been granted Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) for amdizalisib (HMPL-689), a highly selective and potent PI3Kδ inhibitor, for the treatment of relapsed or refractory follicular lymphoma (FL), a subtype of non-Hodgkin’s lymphoma (NHL).  Drug candidates with… Read More

#News #Trending News

#Biosciences #CRO #Drug development #Immuno-oncology #Oncology

High demand for preclinical expertise fuels growth for Nottingham CRO 

Nottingham, UK-based contract research organisation (CRO) Cellomatics Biosciences has reported year-on-year organic revenue growth of 30% since its inception in 2015, as demand for its preclinical and early discovery phase laboratory services and expertise continues to increase.   Based at BioCity Nottingham, Cellomatics is a specialist preclinical CRO with expertise in five main therapeutic areas: oncology,… Read More

#News

Covid-19
#Clinical trials #Covid-19 #Drug development #Oncology #Therapeutics

Oncology treatment tested in patients with moderate Covid-19 disease 

Australian clinical-stage drug development company Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate Covid-19 disease. Veyonda currently has two main drug actions – a moderating… Read More

#Covid-19 #News #Trending News

#Drug development #Drug discovery #GlobalData #Novel therapeutics

PD market to reach $1.95 billion in 2030 driven by novel therapies

An upcoming influx of new therapies into the Pompe disease (PD) pipeline in the next decade is expected by GlobalData to provide a significant boost to the treatment market for this inherited, and often fatal, disorder that can greatly damage the heart and skeletal muscles. In fact, the market is expected to… Read More

#News #Trends & Analysis